1例因免疫相关不良事件早发而停用纳武单抗后显示持久缓解的胃癌病例
[A case of gastric cancer showing a durable response after the discontinuation of nivolumab due to the early onset of immune-related adverse events].
作者信息
Tomita Yusaku, Mori Yoshinori, Kanaiwa Hiroki, Yamaguchi Ayana, Kitagawa Mika, Nomura Satoshi, Hirano Atsuyuki, Kimura Yoshihide, Tsuchida Kenji, Seno Kyoji
机构信息
Department of Gastroenterology, Nagoya City University West Medical Center.
出版信息
Nihon Shokakibyo Gakkai Zasshi. 2022;119(6):551-557. doi: 10.11405/nisshoshi.119.551.
The Japanese guidelines for the treatment of gastric cancer recommend nivolumab as third-line chemotherapy for metastatic gastric cancer. We report a case of gastric cancer exhibiting a durable response after the discontinuation of nivolumab due to the early onset of immune-related adverse event (irAE). A 64-year-old man with advanced HER2-positive gastric cancer and distant lymph node metastasis received nivolumab as fourth-line therapy. After two courses of nivolumab, the lymph nodes showed progression. However, the treatment was discontinued because of interstitial pneumonia as an irAE. Disease regression was sustained for approximately 11 months without the readministration of nivolumab.
日本胃癌治疗指南推荐纳武利尤单抗作为转移性胃癌的三线化疗药物。我们报告了1例因免疫相关不良事件（irAE）早发而停用纳武利尤单抗后仍表现出持久反应的胃癌病例。一名64岁的男性，患有晚期HER2阳性胃癌并伴有远处淋巴结转移，接受纳武利尤单抗作为四线治疗。接受两疗程纳武利尤单抗治疗后，淋巴结出现进展。然而，由于irAE导致的间质性肺炎，治疗被中断。在未重新使用纳武利尤单抗的情况下，疾病缓解持续了约11个月。
Zotero 插件